Skip to main content

When to Stop Aspirin Before CABG-Plus-Valve Surgery?

By Will Boggs MD
NEW YORK (Reuters Health) Jan 26 - The risk of bleeding after combined coronary artery bypass graft (CABG) and valve surgery is higher when chronic aspirin therapy is stopped within five days of the operation, compared to when it's stopped at least six days in advance.
The finding is from a review of such surgeries done at the Cleveland Clinic in Ohio, reported by Dr. Leslie Cho and colleagues.
Dr. Cho told Reuters Health by email that surgeons need to weigh the risk of bleeding vs. the benefit of aspirin before combined CABG/valve surgery.
"For example, if the patient has a drug-eluting stent and needs surgery, continuing aspirin makes sense,' Dr. Cho said. "However, if the patient is at high risk of bleeding" - because of anemia or older age, or because the surgery is a redo, for example - "then holding aspirin makes sense."
The data, from 1,963 patients on chronic aspirin therapy who underwent nonemergent CABG/valve surgery, were published online December 22 in the American Journal of Cardiology.
When patients were matched based on propensity scores, there was no difference between early and late aspirin discontinuation groups (i.e., within five days or at least six days pre-op) in the primary endpoint, a composite of in-hospital mortality, myocardial infarction, and stroke.
However, significantly more patients in the late-use group received postoperative transfusions (49% vs 42%, p=0.02), and there was a trend toward more reoperations for bleeding in the late-use group (6.1% vs 3.7%; p=0.08).
Guidelines from the Society of Thoracic Surgeons recommend that aspirin be stopped three to five days before elective CABG, whereas American College of Cardiology/American Heart Association guidelines suggest stopping 7 to 10 days in advance. Neither set of guidelines specifically addresses the issue of patients having combined CABG and valve surgery, the researchers note.
"For many years, surgeons and cardiologist had no real sense of when to stop aspirin," Dr. Cho said. "I hope with our study, they can make a logical decision about when to stop aspirin."
To better define patients' risk, Dr. Cho added, "We are currently planning to do a study looking at the level of aspirin function (arachidonic acid light transmittance aggregometry study) as relates to bleeding outcome."
Labels:

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more